16D0 Brody, Jonathan - Thomas Jefferson University - Thomas Jefferson University
jrb006

Jonathan Brody, PhD

Contact Dr. Brody

1015 Walnut Street
Room 623
Philadelphia, PA 19107

(215) 955-2693

Most Recent Peer-reviewed Publications

  1. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- And tissue-specific microRNAs
  2. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
  3. Novel targets in pancreatic cancer research
  4. Studying RNA-binding protein interactions with target mRNAs in eukaryotic cells: Native ribonucleoprotein immunoprecipitation (RIP) assays
  5. MUC1 promoter-driven DTA as a targeted therapeutic strategy against pancreatic cancer
  6. Upgrading gemcitabine with recycled kinase inhibitors
  7. Argonaute CLIP-Seq reveals miRNA targetome diversity across tissue types
  8. HuR posttranscriptionally regulates WEE1: Implications for the DNA damage response in pancreatic cancer cells
  9. Commentary : Fusing transcriptomics to progressive prostate cancer
  10. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer
  11. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: A dual-institutional follow-up with the RTOG 9704 trial
  12. PARP inhibitors for chemoprevention - Letter
  13. Structural implications for selective targeting of PARPs
  14. Targeting cell cycle and hormone receptor pathways in cancer
  15. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival
  16. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer
  17. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer
  18. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
  19. Dual roles of PARP-1 promote cancer growth and progression
  20. Pancreatic cancer and premalignant tumors: Molecular aspects
0